New York Life Investment Management LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 38,383 shares of the company's stock, valued at approximately $454,000.
Other hedge funds also recently made changes to their positions in the company. Creative Planning lifted its holdings in Roivant Sciences by 47.5% in the third quarter. Creative Planning now owns 23,541 shares of the company's stock worth $272,000 after purchasing an additional 7,579 shares during the period. State of Alaska Department of Revenue lifted its stake in shares of Roivant Sciences by 37.0% in the 3rd quarter. State of Alaska Department of Revenue now owns 50,675 shares of the company's stock worth $584,000 after acquiring an additional 13,675 shares during the period. New York State Teachers Retirement System lifted its stake in shares of Roivant Sciences by 11.9% in the 3rd quarter. New York State Teachers Retirement System now owns 249,261 shares of the company's stock worth $2,876,000 after acquiring an additional 26,485 shares during the period. First Trust Direct Indexing L.P. bought a new position in shares of Roivant Sciences in the third quarter valued at approximately $119,000. Finally, US Bancorp DE increased its stake in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after acquiring an additional 1,948 shares during the period. Institutional investors own 64.76% of the company's stock.
Insiders Place Their Bets
In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the transaction, the chief operating officer now directly owns 896,869 shares in the company, valued at approximately $9,551,654.85. The trade was a 10.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CIO Mayukh Sukhatme sold 412,584 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at approximately $226,980,391.35. The trade was a 2.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,388,170 shares of company stock worth $27,612,299. 7.90% of the stock is owned by insiders.
Roivant Sciences Stock Up 0.4 %
Roivant Sciences stock traded up $0.04 during mid-day trading on Friday, hitting $10.64. The company's stock had a trading volume of 4,266,155 shares, compared to its average volume of 4,417,301. The stock has a market capitalization of $7.59 billion, a P/E ratio of -70.93 and a beta of 1.26. Roivant Sciences Ltd. has a twelve month low of $9.76 and a twelve month high of $13.06. The stock's fifty day moving average price is $10.93 and its two-hundred day moving average price is $11.55.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts have issued reports on ROIV shares. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $18.08.
Get Our Latest Stock Analysis on Roivant Sciences
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
